{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T02:18:59Z","timestamp":1758593939679,"version":"3.44.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.critrevonc.2025.104810","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T02:44:30Z","timestamp":1750128270000},"page":"104810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The molecules with double-edged sword roles in T cell: An implication for adoptive T cell therapy"],"prefix":"10.1016","volume":"214","author":[{"given":"Marziyeh","family":"Samiee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeedeh","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila Mohamed","family":"Khosroshahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahereh","family":"Soltantoyeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104810_bib1","first-page":"8","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","author":"Acharya","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104810_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104810_bib3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib4","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.3389\/fimmu.2018.02809","article-title":"The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment","volume":"9","author":"Agresta","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib5","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1158\/1078-0432.CCR-08-2810","article-title":"2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells","volume":"15","author":"Altvater","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104810_bib6","doi-asserted-by":"crossref","first-page":"9087816","DOI":"10.1155\/2021\/9087816","article-title":"The signaling pathway of PGE2 and its regulatory role in T cell differentiation","volume":"2021","author":"An","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.critrevonc.2025.104810_bib7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/eji.200939842","article-title":"T-bet, a Th1 transcription factor regulates the expression of Tim-3","volume":"40","author":"Anderson","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.immuni.2007.03.004","article-title":"Tim protein structures reveal a unique face for ligand binding","volume":"26","author":"Anderson","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104810_bib9","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.4049\/jimmunol.175.4.2045","article-title":"2B4\/CD48-mediated regulation of lymphocyte activation and function 1","volume":"175","author":"Assarsson","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4049\/jimmunol.173.1.174","article-title":"NK cells stimulate proliferation of T and NK cells through 2B4\/CD48 interactions1","volume":"173","author":"Assarsson","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib11","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s11033-024-09839-1","article-title":"Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS","volume":"51","author":"Atif","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104810_bib12","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1073\/pnas.1712107115","article-title":"Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion","volume":"115","author":"Avery","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2025.104810_bib13","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-immunol-090222-110914","article-title":"T cell exhaustion","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.critrevonc.2025.104810_bib15","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.4049\/jimmunol.1502643","article-title":"Genetic and epigenetic regulation of PD-1 expression","volume":"196","author":"Bally","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2018.00043","article-title":"Understanding the Role of Adenosine A2AR Heteroreceptor Complexes in Neurodegeneration and Neuroinflammation","volume":"12","author":"Borroto-Escuela","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.critrevonc.2025.104810_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/PPO.0000000000000059","article-title":"Biochemical signaling of PD-1 on T cells and its functional implications","volume":"20","author":"Boussiotis","year":"2014","journal-title":"Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104810_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071755","article-title":"Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer","volume":"12","author":"Buller","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104810_bib20","doi-asserted-by":"crossref","first-page":"2376782","DOI":"10.1080\/2162402X.2024.2376782","article-title":"Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes","volume":"13","author":"Cadiou","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2025.104810_bib21","first-page":"8","article-title":"Human adenosine A2A receptor: molecular mechanism of ligand binding and activation","author":"Carpenter","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib22","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fphar.2017.00898","article-title":"Human adenosine A(2A) receptor: molecular mechanism of ligand binding and activation","volume":"8","author":"Carpenter","year":"2017","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.104810_bib23","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1158\/0008-5472.CAN-13-3581","article-title":"Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment","volume":"74","author":"Cekic","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104810_bib24","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1084\/jem.20130249","article-title":"Extracellular adenosine regulates naive T cell development and peripheral maintenance","volume":"210","author":"Cekic","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2025.104810_bib25","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.celrep.2019.05.041","article-title":"Quantitative interactomics in primary T cells provides a rationale for concomitant PD-1 and BTLA coinhibitor blockade in cancer immunotherapy","volume":"27","author":"Celis-Gutierrez","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2025.104810_bib26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation1","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.3831","article-title":"Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection","volume":"21","author":"Chen","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104810_bib28","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00018-020-03737-y","article-title":"Transcriptional and epigenetic regulation of PD-1 expression","volume":"78","author":"Chi","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.critrevonc.2025.104810_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14712598.2020.1749593","article-title":"Nivolumab for the treatment of hepatocellular carcinoma","volume":"20","author":"Chiew Woon","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104810_bib30","doi-asserted-by":"crossref","first-page":"8159","DOI":"10.4049\/jimmunol.180.12.8159","article-title":"Molecular basis of the dual functions of 2B4 (CD244)1","volume":"180","author":"Chlewicki","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104810_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/gene.2016.6","article-title":"DNA demethylation of the TIM-3 promoter is critical for its stable expression on T cells","volume":"17","author":"Chou","year":"2016","journal-title":"Genes Immun."},{"key":"10.1016\/j.critrevonc.2025.104810_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063207","article-title":"Simultaneous genetic ablation of PD-1, LAG-3, and TIM-3 in CD8 T cells delays tumor growth and improves survival outcome","volume":"23","author":"Ciraolo","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104810_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2025.104810_bib35","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.0903059","article-title":"T cell\/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells","volume":"184","author":"Dekruyff","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib36","doi-asserted-by":"crossref","first-page":"eadf2223","DOI":"10.1126\/sciimmunol.adf2223","article-title":"Beyond T cell exhaustion: TIM-3 regulation of myeloid cells","volume":"9","author":"Dixon","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200626120","article-title":"Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression","volume":"120","author":"D\u00f6tsch","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2025.104810_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030645","article-title":"TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action","volume":"18","author":"Du","year":"2017","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104810_bib39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fnins.2019.00683","article-title":"On the role of adenosine A2A receptor gene transcriptional regulation in Parkinson's disease","volume":"13","author":"Falconi","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.critrevonc.2025.104810_bib40","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41586-020-2851-2","article-title":"Immune receptor inhibition through enforced phosphatase recruitment","volume":"586","author":"Fernandes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104810_bib41","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2025.104810_bib42","doi-asserted-by":"crossref","first-page":"9313","DOI":"10.1021\/acs.jmedchem.3c00655","article-title":"Targeting EP2 receptor for drug discovery: strengths, weaknesses, opportunities, and threats (SWOT) analysis","volume":"66","author":"Ganesh","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2025.104810_bib43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/intimm\/dxq049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","author":"Ghiotto","year":"2010","journal-title":"Int. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib44","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104810_bib45","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1038\/s41467-019-09883-7","article-title":"IL-1\u03b2, IL-23, and TGF-\u03b2 drive plasticity of human ILC2s towards IL-17-producing ILCs in nasal inflammation","volume":"10","author":"Golebski","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104810_bib46","doi-asserted-by":"crossref","first-page":"27359","DOI":"10.18632\/oncotarget.4751","article-title":"LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104810_bib47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104810_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12974-016-0512-z","article-title":"Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation","volume":"13","author":"Ingwersen","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.critrevonc.2025.104810_bib49","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"Embo J."},{"key":"10.1016\/j.critrevonc.2025.104810_bib50","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1016\/j.jcyt.2024.03.340","article-title":"Multiplex Gene editing in car t cells","volume":"26","author":"Jafarzadeh","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2025.104810_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104810_bib52","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2025.104810_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13321-021-00492-5","article-title":"Structure-based identification of dual ligands at the A2AR and PDE10A with anti-proliferative effects in lung cancer cell-lines","volume":"13","author":"Kalash","year":"2021","journal-title":"J. Chemin.."},{"key":"10.1016\/j.critrevonc.2025.104810_bib54","doi-asserted-by":"crossref","first-page":"eaba6006","DOI":"10.1126\/scitranslmed.aba6006","article-title":"Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice","volume":"13","author":"Kalia","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104810_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.745286","article-title":"Engineered removal of PD-1 from the surface of CD19 CAR-T cells results in increased activation and diminished survival","volume":"8","author":"Kalinin","year":"2021","journal-title":"Front Mol. Biosci."},{"key":"10.1016\/j.critrevonc.2025.104810_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101296","article-title":"CEACAM1 structure and function in immunity and its therapeutic implications","volume":"42","author":"Kim","year":"2019","journal-title":"Semin Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib57","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","article-title":"The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands","volume":"181","author":"Kinter","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib58","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1128\/MCB.05297-11","article-title":"Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways","volume":"31","author":"Lee","year":"2011","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104810_bib60","first-page":"xi12","article-title":"35O - Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","volume":"30","author":"Lin","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12731","article-title":"Seminal immunologic discoveries with direct clinical implications: the 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy","volume":"88","author":"Ljunggren","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib62","series-title":"Encyclopedia of Signaling Molecules. New York, NY","article-title":"Prostaglandin E2 Receptor EP2 Subtype","author":"Luo","year":"2016"},{"key":"10.1016\/j.critrevonc.2025.104810_bib63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12974-016-0645-0","article-title":"Long-term exposure to PGE2 causes homologous desensitization of receptor-mediated activation of protein kinase A","volume":"13","author":"Malty","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.critrevonc.2025.104810_bib64","doi-asserted-by":"crossref","first-page":"1873607","DOI":"10.1080\/2162402X.2021.1873607","article-title":"Addition of anti-TIM3 or anti-TIGIT antibodies to anti-PD1 blockade augments human T cell adoptive cell transfer","volume":"10","author":"Martinez","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2025.104810_bib65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13046-020-01546-6","article-title":"Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells","volume":"39","author":"Masoumi","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104810_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111669","article-title":"Imaging of biphasic signalosomes constructed by checkpoint receptor 2B4 in conventional and chimeric antigen receptor-T cells","volume":"28","author":"Matsushima","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2025.104810_bib67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clim.2016.01.008","article-title":"Roles of CD48 in regulating immunity and tolerance","volume":"164","author":"Mcardel","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109120","article-title":"Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells","volume":"35","author":"Mclane","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2025.104810_bib69","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.molimm.2004.07.032","article-title":"2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells","volume":"42","author":"Mcnerney","year":"2005","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib70","series-title":"The Adenosine Receptors","article-title":"Adenosine Receptors: Structure, Distribution, and Signal Transduction","author":"Merighi","year":"2018"},{"key":"10.1016\/j.critrevonc.2025.104810_bib71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-1-4939-8751-1_14","article-title":"Epigenetic and genetic regulation of PDCD1 gene in cancer immunology","volume":"1856","author":"Mishra","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib72","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.4049\/jimmunol.1102609","article-title":"Antigen-independent induction of Tim-3 expression on human T cells by the common \u03b3-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway","volume":"188","author":"Mujib","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib73","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1158\/0008-5472.CAN-11-1487","article-title":"Prospects for TIM3-targeted antitumor immunotherapy","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104810_bib74","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104810_bib75","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20142237","article-title":"Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells","volume":"212","author":"Odorizzi","year":"2015","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.critrevonc.2025.104810_bib76","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.4049\/jimmunol.0901247","article-title":"A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments","volume":"183","author":"Ohta","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib77","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib78","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab plus relatlimab: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2025.104810_bib79","article-title":"Adoptive cellular transfer immunotherapies for cancer","volume":"32","author":"Parsonidis","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.critrevonc.2025.104810_bib80","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104810_bib81","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s42003-020-0845-0","article-title":"Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation","volume":"3","author":"Patsoukis","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib82","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00262-017-2039-2","article-title":"CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases","volume":"66","author":"Paulsen","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104810_bib83","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1385690","article-title":"Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy","volume":"7","author":"Sabatos-Peyton","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2025.104810_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082274","article-title":"Mechanisms of T-cell exhaustion in pancreatic cancer","volume":"12","author":"Saka","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104810_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8010071","article-title":"Transcriptomic profiling of tumor-infiltrating CD4(+)TIM-3(+) T cells reveals their suppressive, exhausted, and metastatic characteristics in colorectal cancer patients","volume":"8","author":"Sasidharan Nair","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.critrevonc.2025.104810_bib86","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","article-title":"Coinhibitory pathways in the B7-CD28 ligand-receptor family","volume":"44","author":"Schildberg","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104810_bib87","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/geno.1994.1562","article-title":"Structure and chromosomal localization of the human PD-1 gene (PDCD1)","volume":"23","author":"Shinohara","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.critrevonc.2025.104810_bib88","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib89","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/icb.2011.75","article-title":"Prostaglandin E2 and T cells: friends or foes?","volume":"90","author":"Sreeramkumar","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/icb.2015.62","article-title":"Efficient T-cell priming and activation requires signaling through prostaglandin E2 (EP) receptors","volume":"94","author":"Sreeramkumar","year":"2016","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib91","first-page":"1203","article-title":"Prostaglandin EP2 receptor: novel therapeutic target for human cancers (Review)","volume":"42","author":"Sun","year":"2018","journal-title":"Int J. Mol. Med"},{"key":"10.1016\/j.critrevonc.2025.104810_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101302","article-title":"Tim-3: a co-receptor with diverse roles in T cell exhaustion and tolerance","volume":"42","author":"Tang","year":"2019","journal-title":"Semin Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib94","first-page":"15","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","author":"Tao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib95","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jsbmb.2012.07.007","article-title":"Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer","volume":"132","author":"To","year":"2012","journal-title":"J. Steroid Biochem Mol. Biol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib96","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1038\/s41467-023-42734-0","article-title":"A(2A)R eGFP reporter mouse enables elucidation of A(2A)R expression dynamics during anti-tumor immune responses","volume":"14","author":"Todd","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104810_bib97","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/intimm\/dxz021","article-title":"Molecular mechanisms underlying prostaglandin E2-exacerbated inflammation and immune diseases","volume":"31","author":"Tsuge","year":"2019","journal-title":"Int. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib98","first-page":"10","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial","author":"Tykodi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104810_bib99","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fimmu.2016.00004","article-title":"Responses to microbial challenges by SLAMF receptors","volume":"7","author":"Van Driel","year":"2016","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib100","doi-asserted-by":"crossref","first-page":"eadm8660","DOI":"10.1126\/sciadv.adm8660","article-title":"Targeting conserved TIM3(+)VISTA(+) tumor-associated macrophages overcomes resistance to cancer immunotherapy","volume":"10","author":"Vanmeerbeek","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2025.104810_bib101","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3389\/fimmu.2012.00377","article-title":"Evolving role of 2B4\/CD244 in T and NK cell responses during virus infection","volume":"3","author":"Waggoner","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib102","first-page":"3","article-title":"Evolving role of 2B4\/CD244 in T and NK cell responses during virus infection","author":"Waggoner","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib103","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-021-00346-0","article-title":"The role of phosphatidylserine on the membrane in immunity and blood coagulation","volume":"10","author":"Wang","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2025.104810_bib104","article-title":"Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors","volume":"38","author":"Wang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s40425-019-0685-y","article-title":"PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity","volume":"7","author":"Wei","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104810_bib106","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2009.08.005","article-title":"Blimp hovers over T cell immunity","volume":"31","author":"Welsh","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104810_bib107","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib108","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104810_bib109","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104810_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672328","article-title":"Epigenetic regulation of NK cell-mediated antitumor immunity","volume":"12","author":"Xia","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib111","article-title":"Establishment of novel anti-TIM-3 antibodies interfering with its binding to ligands","volume":"10","author":"Yan","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2025.104810_bib112","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","article-title":"A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment","volume":"78","author":"Young","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104810_bib113","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","article-title":"Disturbed mitochondrial dynamics in CD8(+) TILs reinforce T cell exhaustion","volume":"21","author":"Yu","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib114","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12935-020-01380-y","article-title":"SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer","volume":"20","author":"Zhang","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.critrevonc.2025.104810_bib115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","article-title":"Structural and functional analysis of the costimulatory receptor programmed death-1","volume":"20","author":"Zhang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104810_bib116","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib117","first-page":"7","article-title":"Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion","author":"Zhu","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2025.104810_bib118","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13045-017-0486-z","article-title":"Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia","volume":"10","author":"Zhu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104810_bib119","first-page":"14","article-title":"The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer","author":"Zohair","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:14:49Z","timestamp":1758590089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":119,"alternative-id":["S1040842825001982"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104810","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The molecules with double-edged sword roles in T cell: An implication for adoptive T cell therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104810"}}